Can afatinib treat advanced lung cancer?

Afatinib can treat advanced non-small cell lung cancer (NSCLC). NSCLC is a type of lung cancer and usually accounts for the majority of lung cancer diagnoses. Afatinib is an oral targeted therapy that targets a specific protein kinase in tumor cells called epidermal growth factor receptor (EGFR). In some patients, mutations in the EGFR gene exist in NSCLC cells, leading to abnormal signaling and promoting the growth and spread of tumor cells. Afatinib can interfere with the growth of tumor cells by inhibiting the activity of EGFR, thereby slowing or inhibiting the development of tumors. Afatinib has proven to be an effective treatment option for patients with advanced EGFR variant-positive NSCLC. In terms of treatment, doctors will choose whether to use afatinib or other treatment options, such as chemotherapy, radiotherapy or other targeted therapy drugs, based on the patient's specific situation and condition.